With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

26/03/2015 - 2 minutes

Exactly one month ago, the article “Cellectis is preparing its IPO in the U.S” explained Cellectis prepared an  IPO to be listed on the NASDAQ. Yesterday, the company announced the pricing of its initial public offering. Its goal is to raise €197M and up to €226.8M in case of allotment. A large amount of ressources to move forwards and become the leading CAR-T Biotech company.

The technology developed by Cellectis aims at reprogramming T lymphocytes, an essential player of the human immune system. Ultimately, the company’s approach intends that the reprogrammed T-cells to create an antibody which can recognize the protein indicating a cancer cell. The T lymphocytes could then destroy the cell in question. Thanks to this technology, the company has already signed partnerships with Servier which has promised up to €1Bn for 6 targets and more recently with Pfizer (for €2.6Bn) to collaborate and open a new laboratory in New York in the same building as the US pharmaceutical group.

Cellectis has several competitors including BlueBird Bio (see our interview here),

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member